How Useful is Anti-TNF Serum Level and Anti-drug Antibodies Detection in Evaluating Patients with Spondyloarthritis?

Deaconu, Claudia; Opriş, D.; Mazilu, Diana; Borangiu, A.; Groşeanu, L.; Saulescu, I.; Gainaru, C.; Negru, Magdalena; Constantinescu, C; Bojincă, V.; Vlad, Violeta; Bălănescu, Andra; Predeţeanu, Denisa; Rux,; Ionescu, R.

doi:10.4172/2167-7921.1000162

Cited by 2 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other reasons could be due to the type of detection methods used or the time at which the sample was collected. 23 However, a significant association between an increase in disease activity and the presence of anti-infliximab antibodies was reported by several other studies. 21,24,26 The presence of anti-drug antibodies could be the reason for unresponsiveness to treatment.…”

Section: Resultsmentioning

confidence: 89%

“…21,22 Another study reported that the presence of anti-infliximab antibodies can have a positive correlation with CRP levels, not with ESR levels, this may lead to confusion about which inflammatory markers reflecting the non-responsiveness to biological therapy more precisely. 23 There was no significant association (p > 0.05) between the occurrence of anti-infliximab antibodies and treatment-related factors (Table 3). The data show 73.7% of patients with positive anti-infliximab antibodies had unsatisfactory concentrations of infliximab, whereas 26.3% had a satisfactory concentration of infliximab.…”

Section: Resultsmentioning

confidence: 90%

“…21,24,26 The presence of anti-drug antibodies could be the reason for unresponsiveness to treatment. 23 The majority of patients with anti-infliximab antibodies had a high result of both ESR 73.7% and CRP 57.9%. Although non-significantly associated with the occurrence of anti-infliximab antibodies, the presence of this high level of both parameters could be due to the presence of anti-drug antibodies which may increase the markers of inflammation.…”

Section: Resultsmentioning

confidence: 93%

“…20 Other studies showed different percentages that ranged between 11.7% to 48%. 21,22,23 This variation in the reported percentages of anti-drug antibodies among the studies could be due to the presence of several factors that affect the detection of these antibodies such as the techniques used. 19,24 Several factors may have an effect on the immunogenicity of biological drugs such as factors related to the treatment; dose, route and duration of administration of the biological drugs and whether they are continuous or intermittent.…”

Section: Resultsmentioning

confidence: 99%

“…The absence of significant association made it similar to other findings 22 which contributed such an effect to the study design. With the cross-sectional study, there was only a single assessment of efficacy and health outcome analysis without follow up over time 23 similar to our study design. Other reasons could be due to the type of detection methods used or the time at which the sample was collected.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Detection of Anti-Infliximab Antibodies and Identifying Factors affecting their Occurrence Using Elisa Method among Patients with Immune-Mediated Inflammatory Diseases

Kasim¹,

Eassa²,

Salih³

2021

Indian Journal of Forensic Medicine & Toxicology

View full text Add to dashboard Cite

Background: Biological disease-modifying anti-rheumatic drugs such as infliximab are often associated with the development of anti-drug antibodies. Such a problem should be monitored in patients on these drugs. The purpose of the present study was to detect anti-infliximab antibodies and identifying factors affecting their occurrence, together with measuring infliximab concentration in the serum of patients with immune-mediated inflammatory diseases. Methods:A cross-sectional study was conducted between December 2018 to October 2019 at the Specialized Center of Rheumatic Diseases and Medical Rehabilitation in Duhok, Iraq. The included patients were of both genders, aged between 20-70 years, diagnosed with any type of immune-mediated inflammatory diseases for at least one year and had been taking infliximab with or without conventional drugs for at least 3 months. Disease activity scales specific to each disease condition were used. Anti-infliximab antibodies and infliximab concentrations in the serum were measured by using the sandwich ELISA method. Results: Anti-infliximab antibodies were detected in 19/31 (61.3%) of patients treated with infliximab, and 25/31 (80.6%) of them had an unsatisfactory infliximab concentration in the serum (< 3 μg/mL). Short duration (< 10 years) of the disease was significantly associated (p < 0.05) with positive anti-infliximab antibodies. A non-significant association (p > 0.05) was reported between the occurrence of anti-infliximab antibodies and other examined factors. High percentages of patients (57.9%) with positive anti-infliximab antibodies had moderate to high disease activity. Unsatisfactory infliximab concentration was found in 73.7% of these patients. The non-users of methotrexate and other conventional synthetic disease-modifying anti-rheumatic drugs comprised 78.9% and 68.4% of patients who had antibodies to infliximab, respectively. Conclusions: Anti-infliximab antibodies were positive in more than half of the examined patients, and most of them had unsatisfactory infliximab serum concentrations. Further efforts are needed to provide biological drugs regularly, using at least one of the conventional synthetic disease-modifying anti-rheumatic drugs to reduce the development of anti-infliximab antibodies. Regular measurement of anti-drug antibodies and biological drugs concentrations are essential to earn the goal of therapy.

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Detection of Anti-Infliximab Antibodies and Identifying Factors affecting their Occurrence Using Elisa Method among Patients with Immune-Mediated Inflammatory Diseases

Kasim¹,

Eassa²,

Salih³

2021

Indian Journal of Forensic Medicine & Toxicology

View full text Add to dashboard Cite

show abstract

Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it

Padilla-Martínez

Romero-Sánchez

Bello-Gualtero

et al. 2019

CRR

View full text Add to dashboard Cite

Background: Many patients may have resistance to TNF-blockers. These drugs may induce neutralizing antibodies. The determination of the drug levels of TNF-blockers and Anti-Drug Antibodies (ADAs) against TNF-blockers may help to make clinical decisions. Objectives: The objective of this study was to associate and predict the drug levels of TNFblockers and ADAs in relation to disease activity in patients with Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA). Methods: Cross-sectional study including patients fulfilling ASAS classification criteria for SpA and 2010 ACR-EULAR classification criteria for RA. These patients were treated with Adalimumab (ADA), Infliximab (IFX), and Etanercept (ETN). A bivariate analysis and the chi-square test were performed to evaluate the association of ADAs and drug levels with activity measures for SpA and RA. Five regression models analyzing drug levels, ADAs and disease activity measures using a multiple linear regression were performed in order to evaluate the prediction of ADAs and drug levels in relation to disease activity. Results: In SpA, IFX levels were associated with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (p=0.034). In RA, total drug levels were associated with DAS28-ESR (28 joint Disease activity Score-erythrocyte sedimentation rate), (p=0.008), DAS28-CRP (p=0.042), CDAI (Clinical Disease Activity Index) (p=0.047) and SDAI (Simple Disease activity index), (p=0.017). ADA levels had association with CDAI (p=0.002) and SDAI (p=0.002). IFX levels were associated with a DAS28-ESR (p=0.044), DAS28-CRP (p=0.022) and SDAI (p=0.022). ADAs were associated in SpA with BASDAI (p=0.027). Drug levels and ADAs did not predict disease activity in patients with SpA or RA. Conclusions: ADAs and drug levels of anti-TNF are associated with disease activity measures in patients with SpA and RA. However, they cannot predict clinical activity in these conditions.

show abstract

How Useful is Anti-TNF Serum Level and Anti-drug Antibodies Detection in Evaluating Patients with Spondyloarthritis?

Cited by 2 publications

References 0 publications

Detection of Anti-Infliximab Antibodies and Identifying Factors affecting their Occurrence Using Elisa Method among Patients with Immune-Mediated Inflammatory Diseases

Detection of Anti-Infliximab Antibodies and Identifying Factors affecting their Occurrence Using Elisa Method among Patients with Immune-Mediated Inflammatory Diseases

Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it

Contact Info

Product

Resources

About